Fate Therapeutics (FATE) Tops Q2 EPS by 5c
Tweet
Share
E-mail
Get Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.05 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $1.91 million versus the consensus estimate of $850.68 thousand.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Investing.com’s stocks of the week
- Oceanfirst Financial (OCFC) Reports In-Line Q2 EPS
- TFS Financial (TFSL) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
